Ambee Pharmaceuticals PLC
DDSE:AMBEEPHA736.50
BDT
+1.80
(+0.24%)
ISIN
BD0451AMBPH6
Return %
Stock
S&P 500
1Y
-7.39
14.20
3Y
-16.72
81.12
5Y
59.83
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Kazi Tanzzina Ferdous
- Full Time Employees
- 474
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Dhaka Bangladesh
- Website
- ambeepharma.com
- Similar Companies
- Business
- Ambee Pharmaceuticals PLC is a Bangladesh-based pharmaceutical manufacturing company engaged in the development, production, marketing, and commercial distribution of prescription drugs, over-the-counter medicines, and generic healthcare formulations. The company manufactures and markets a diverse portfolio of finished pharmaceutical formulations across numerous therapeutic segments, including antispasmodics, such as Drotaverine Hydrochloride sold under the No-Spa brand; analgesics, antipyretics, and anti-inflammatory agents, including Paracetamol and Caffeine under the Act Plus brand, Paracetamol under the Act brand, and Ketorolak Tromethamine under the Arolak brand; gastrointestinal treatments and anti-ulcerants, including Esomeprazole Magnesium Trihydrate under the X-Pro brand, as well as Aluctin; antibacterial, antifungal, and antiprotozoal therapeutics, including Metronidazole under the Klion brand, Ciprofloxacin under the Hiflox brand, Levofloxacin under the Lexlo brand, Doxycycline under the Doxilin brand, and Fluconazole under the Afluzole brand; vitamin, mineral, and hematinic supplements, including Zinc Sulphate Monohydrate under the Zinc-S brand, multivitamin and mineral complexes under the Vitex and Vitex Gold brands, and calcium combinations under the Ambeecal and Ambeecal-D brands; psychotropic and central nervous system therapeutics, including Diazepam under the Seduxen brand, Noctin, and Diphedan; cardiovascular and diuretic medications, including Spironolactone under the Verospiron and Verospiron Plus brands, and Lotas; respiratory, antihistamine, and antiallergic agents, including Fexofenadine under the Ambfex brand, Cetirizine under the Actizen brand, and Ambkust; and corticosteroids and anthelmintics, including Prednisolone, Amason, and Triben. The company offers its products across multiple dosage forms, including oral solid dosage tablets and capsules, oral liquid syrups and suspensions, topical gels, and sterile injectables. The company operates a central manufacturing facility located in the Tejgaon Industrial Area of Dhaka, adhering to Current Good Manufacturing Practices (cGMP) standards and ISO 9001 certified quality management systems. Ambee Pharmaceuticals PLC maintains a long-standing technical and manufacturing collaboration with Hungarian pharmaceutical enterprise Medimpex, supporting the formulation and production of specialized European-origin therapeutics. The company serves the domestic healthcare sector across Bangladesh, distributing its finished pharmaceuticals to retail pharmacy networks, public and private hospitals, government healthcare institutions, and non-governmental health organizations. In recent developments, the company executed a corporate re-registration to convert its legal status from Ambee Pharmaceuticals Limited to Ambee Pharmaceuticals PLC in alignment with statutory corporate governance amendments in Bangladesh. Operationally, the company has implemented infrastructure and equipment modernization initiatives across its Tejgaon manufacturing facility, upgrading cleanroom environments, HVAC systems, and laboratory testing equipment to enhance Current Good Manufacturing Practice compliance, production efficiency, and quality control capabilities. Additionally, Ambee Pharmaceuticals PLC has continued to broaden its generic product portfolio through the rollout of line extensions in high-demand therapeutic areas, including gastrointestinal therapies, pain management agents, and nutritional formulations, while expanding its regional distribution logistics and institutional sales reach across Bangladesh. Ambee Pharmaceuticals PLC was incorporated on February 4, 1976, and is headquartered in Dhaka, Bangladesh. The company is publicly listed on the Dhaka Stock Exchange and the Chittagong Stock Exchange under the ticker symbol AMBEEPHA.